Labcorp Holdings annual cash and equivalents
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Labcorp Holdings Cash & Equivalents Growth & History (LH)
Labcorp Holdings's cash and equivalents was $532.3M for fiscal 2025.
View full Labcorp Holdings company overviewLabcorp Holdings annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $532.3M | −$986.4M | −64.95% |
| 2024 | 2024-12-31 | $1.52B | $981.9M | +182.92% |
| 2023 | 2023-12-31 | $536.8M | $216.2M | +67.44% |
| 2022 | 2022-12-31 | $320.6M | −$1.15B | −78.23% |
| 2021 | 2021-12-31 | $1.47B | $151.9M | +11.50% |
| 2020 | 2020-12-31 | $1.32B | $983.3M | +291.35% |
| 2019 | 2019-12-31 | $337.5M | −$89.3M | −20.92% |
| 2018 | 2018-12-31 | $426.8M | $110.2M | +34.81% |
| 2017 | 2017-12-31 | $316.6M | −$117.0M | −26.98% |
| 2016 | 2016-12-31 | $433.6M | −$282.8M | −39.48% |
| 2015 | 2015-12-31 | $716.4M | $136.4M | +23.52% |
| 2014 | 2014-12-31 | $580.0M | $176.0M | +43.56% |
| 2013 | 2013-12-31 | $404.0M | $0 | 0.00% |
| 2012 | 2012-12-31 | $404.0M | $244.7M | +153.61% |
| 2011 | 2011-12-31 | $159.3M | $0 | 0.00% |
| 2010 | 2010-12-31 | $159.3M | $10.8M | +7.27% |
| 2009 | 2009-12-31 | $148.5M | −$71.2M | −32.41% |
| 2008 | 2008-12-31 | $219.7M | $163.3M | +289.54% |
| 2007 | 2007-12-31 | $56.4M | — | — |
Labcorp Holdings quarterly cash and equivalents
Q4.08
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $141.8M | −$505.5M | −78.09% |
| Q1 2026 | 2026-03-31 | $981.1M | $611.7M | +165.59% |
| Q4 2025 | 2025-12-31 | $532.3M | −$986.4M | −64.95% |
| Q3 2025 | 2025-09-30 | $598.1M | −$919.2M | −60.58% |
| Q2 2025 | 2025-06-30 | $647.3M | $382.2M | +144.17% |
| Q1 2025 | 2025-03-31 | $369.4M | $270.1M | +272.00% |
| Q4 2024 | 2024-12-31 | $1.52B | $981.9M | +182.92% |
| Q3 2024 | 2024-09-30 | $1.52B | $789.4M | +108.45% |
| Q2 2024 | 2024-06-30 | $265.1M | −$1.67B | −86.27% |
| Q1 2024 | 2024-03-31 | $99.3M | −$294.6M | −74.79% |
| Q4 2023 | 2023-12-31 | $536.8M | $216.2M | +67.44% |
| Q3 2023 | 2023-09-30 | $727.9M | $318.0M | +77.58% |
| Q2 2023 | 2023-06-30 | $1.93B | $861.8M | +80.63% |
| Q1 2023 | 2023-03-31 | $393.9M | −$839.6M | −68.07% |
| Q4 2022 | 2022-12-31 | $320.6M | −$1.15B | −78.23% |
| Q3 2022 | 2022-09-30 | $409.9M | −$1.63B | −79.87% |
| Q2 2022 | 2022-06-30 | $1.07B | −$894.4M | −45.56% |
| Q1 2022 | 2022-03-31 | $1.23B | −$657.3M | −34.76% |
| Q4 2021 | 2021-12-31 | $1.47B | $151.9M | +11.50% |
| Q3 2021 | 2021-09-30 | $2.04B | $1.37B | +205.23% |
| Q2 2021 | 2021-06-30 | $1.96B | $1.41B | +252.46% |
| Q1 2021 | 2021-03-31 | $1.89B | $1.57B | +484.30% |
| Q4 2020 | 2020-12-31 | $1.32B | $983.3M | +291.35% |
| Q3 2020 | 2020-09-30 | $667.2M | $306.1M | +84.77% |
| Q2 2020 | 2020-06-30 | $557.0M | $291.6M | +109.87% |
| Q1 2020 | 2020-03-31 | $323.6M | −$25.2M | −7.22% |
| Q4 2019 | 2019-12-31 | $337.5M | −$89.3M | −20.92% |
| Q3 2019 | 2019-09-30 | $361.1M | −$531.5M | −59.55% |
| Q2 2019 | 2019-06-30 | $265.4M | −$627.2M | −70.27% |
| Q1 2019 | 2019-03-31 | $348.8M | −$13.0M | −3.59% |
| Q4 2018 | 2018-12-31 | $426.8M | $110.2M | +34.81% |
| Q3 2018 | 2018-09-30 | $892.6M | $483.3M | +118.08% |
| Q2 2018 | 2018-06-30 | $892.6M | $592.7M | +197.63% |
| Q1 2018 | 2018-03-31 | $361.8M | −$3.7M | −1.01% |
| Q4 2017 | 2017-12-31 | $316.6M | −$117.0M | −26.98% |
| Q3 2017 | 2017-09-30 | $409.3M | −$158.3M | −27.89% |
| Q2 2017 | 2017-06-30 | $299.9M | −$339.7M | −53.11% |
| Q1 2017 | 2017-03-31 | $365.5M | −$330.8M | −47.51% |
| Q4 2016 | 2016-12-31 | $433.6M | −$282.8M | −39.48% |
| Q3 2016 | 2016-09-30 | $567.6M | −$145.4M | −20.39% |
| Q2 2016 | 2016-06-30 | $639.6M | $20.6M | +3.33% |
| Q1 2016 | 2016-03-31 | $696.3M | $249.9M | +55.98% |
| Q4 2015 | 2015-12-31 | $716.4M | $136.4M | +23.52% |
| Q3 2015 | 2015-09-30 | $713.0M | $137.3M | +23.85% |
| Q2 2015 | 2015-06-30 | $619.0M | $139.5M | +29.09% |
| Q1 2015 | 2015-03-31 | $446.4M | $107.5M | +31.72% |
| Q4 2014 | 2014-12-31 | $580.0M | $176.0M | +43.56% |
| Q3 2014 | 2014-09-30 | $575.7M | $401.6M | +230.67% |
| Q2 2014 | 2014-06-30 | $479.5M | $368.2M | +330.82% |
| Q1 2014 | 2014-03-31 | $338.9M | $153.1M | +82.40% |
| Q4 2013 | 2013-12-31 | $404.0M | $0 | 0.00% |
| Q3 2013 | 2013-09-30 | $174.1M | −$291.9M | −62.64% |
| Q2 2013 | 2013-06-30 | $111.3M | −$13.1M | −10.53% |
| Q1 2013 | 2013-03-31 | $185.8M | $55.9M | +43.03% |
| Q4 2012 | 2012-12-31 | $404.0M | $244.7M | +153.61% |
| Q3 2012 | 2012-09-30 | $466.0M | $380.2M | +443.12% |
| Q2 2012 | 2012-06-30 | $124.4M | $5.5M | +4.63% |
| Q1 2012 | 2012-03-31 | $129.9M | −$65.5M | −33.52% |
| Q4 2011 | 2011-12-31 | $159.3M | $0 | 0.00% |
| Q3 2011 | 2011-09-30 | $85.8M | −$11.1M | −11.46% |
| Q2 2011 | 2011-06-30 | $118.9M | $15.1M | +14.55% |
| Q1 2011 | 2011-03-31 | $195.4M | $23.2M | +13.47% |
| Q4 2010 | 2010-12-31 | $159.3M | $10.8M | +7.27% |
| Q3 2010 | 2010-09-30 | $96.9M | −$29.9M | −23.58% |
| Q2 2010 | 2010-06-30 | $103.8M | −$122.8M | −54.19% |
| Q1 2010 | 2010-03-31 | $172.2M | — | — |
| Q4 2009 | 2009-12-31 | $148.5M | −$71.2M | −32.41% |
| Q3 2009 | 2009-09-30 | $126.8M | — | — |
| Q2 2009 | 2009-06-30 | $226.6M | — | — |
| Q4 2008 | 2008-12-31 | $219.7M | — | — |
Labcorp Holdings cash and equivalents trends
Over the last five fiscal years, Labcorp Holdings's cash and equivalents decreased from $1.32B to $532.3M, a change of −$788.5M. The latest reported quarter, Q2 2026, shows $141.8M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Labcorp Holdings source filings ↗Community posts
Labcorp sets new medium-term growth targets and reaffirms its annual outlook
Labcorp ($LH) set medium-term targets for annual revenue growth of 5–8% and adjusted earnings-per-share growth of 8.5–11.5% through 2029. The company also reaffirmed its existing 2026 guidance. The new framework describes the performance ma ...
Labcorp acquires MLM Medical Labs to expand clinical-trial services
Labcorp ($LH) acquired MLM Medical Labs, adding central and specialty laboratory operations in the United States, Germany and South Africa. The company said the purchase expands its biomarker-testing capabilities and improves its ability to ...